Cassella James V

Chief Development OfficerCONCERT PHARMACEUTICALS, INC. (CNCE) · full profile →Form 4 · filed Mar 6, 2023
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
10
2 non-derivative · 8 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 6, 2023Disposed to issuer(D)58K0
Mar 6, 2023Tender(U)81K0

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 6, 2023Disposed to issuer(D)42K0
Mar 6, 2023Disposed to issuer(D)140K0
Mar 6, 2023Disposed to issuer(D)50K0
Mar 6, 2023Disposed to issuer(D)70K0
Mar 6, 2023Disposed to issuer(D)50K0
Mar 6, 2023Disposed to issuer(D)75K0
Mar 6, 2023Disposed to issuer(D)35K0
Mar 6, 2023Disposed to issuer(D)60K0

Transaction Codes

D
Disposition to the issuer
U
See SEC Form 4 code table

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001209191-23-016163) within minutes of acceptance. Every field above traces to the original document. Verify it directly: